Thông tin cho nhân viên y tế
Thuốc mới và thông tin từ Drugs.com
- REDWOOD CITY, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a global commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted…
- DUBLIN , August 25, 2026 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration ( FDA ) approved two Ziihera (zanidatamab-hrii)-containing regimens for the first-line treatment of adults…
- SPRING HOUSE, Pa. August 24, 2026 – Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) approval of Imaavy® (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia (wAIHA) – a…
- NOVATO, Calif., August 19, 2026 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Genglycos™ (pariglasgene brecaparvovec-opnr)…
- TARRYTOWN, N.Y., August 19, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has granted approval for Pasatru™ (garetosmab-grts) to reduce formation of new…
- CINCINNATI–(BUSINESS WIRE)–LIB Therapeutics, Inc. (LIB), a privately held biopharmaceutical company with a singular focus on helping high-risk patients achieve their cholesterol goals, today announced the U.S. Food and Drug Administration (FDA)…
- WEDNESDAY, Aug. 26, 2026 — Baseline cortical atrophy measured within the early-onset Alzheimer disease (EOAD) signature, a set of predominantly parietotemporal regions showing greater atrophy in EOAD than in controls, can predict progression from…
- WEDNESDAY, Aug. 26, 2026 — Extreme heat is associated with 33 diagnoses, including multiple sclerosis, injuries, and dermatologic and pressure-related conditions, according to a study published online Aug. 26 in Science Advances.Hyojung Jang, from…
- WEDNESDAY, Aug. 26, 2026 — Strength training during pregnancy may improve some outcomes for women with overweight or obesity, according to a study published online Aug. 19 in Acta Obstetricia et Gynecologica Scandinavica. Teresa E. Santa Cruz…
- WEDNESDAY, Aug. 26, 2026 — Spectacle lenses with highly aspherical lenslets (HAL) are safe and effective for reducing myopia progression in children, according to a study published online Aug. 20 in JAMA Ophthalmology. Jason Shen, Ph.D., from…
- WEDNESDAY, Aug. 26, 2026 — Five-year survivors of Hodgkin lymphoma (HL) diagnosed during adulthood experience nearly twofold higher all-cause mortality than the general population, according to a research letter published online Aug. 18 in JAMA…
- WEDNESDAY, Aug. 26, 2026 — Writing style can explain about half of observed disparities in care team response to messages sent by patients, according to a study published online Aug. 24 in JAMA Network Open. Mitchell Tang, Ph.D., from Harvard…
Thông tin từ The Pharma Letter
- 4basebio and Genezen, a US contract development and manufacturing organization (CDMO), today announced an expanded, non-exclusive collaboration providing drug developers access to 4basebio’s Research Use Only, High-Quality, and GMP-grade hpDNA development and clinical programs.
- US pharma major AbbVie said it has submitted an application to the European Medicines Agency (EMA) seeking approval for Skyrizi (risankizumab) as a subcutaneous induction treatment for adults with moderately to severely active Crohn's disease.
- Redx Pharma, a UK based, privately-held clinical-stage biotechnology, today announced completion of its Series A financing of $36 million.
- French clinical-stage biotech Osivax and South Korean biopharmaceutical company GC Biopharma have entered a long-term collaboration to develop and commercialize a next-generation seasonal influenza vaccine.
- US pharma major Eli Lilly said a real-world study of adults over 55 with overweight or obesity found that sustained use of Zepbound (tirzepatide) for weight management was associated with lower healthcare costs over time compared with similar untreated adults, driven partly by fewer hospital admissions and emergency department visits.
- Positive high-level results from the Phase III CROSSING trial in patients with eosinophilic esophagitis (EoE) showed that AstraZeneca and Amgen’s Tezspire (tezepelumab) demonstrated statistically-significant and clinically-meaningful improvements across both co-primary and all key secondary endpoints at week 24, which were sustained through week 52 in both doses tested.
Thông tin từ BioPharmaDive
- Rasonque’s speedy approval — just a month after a completed submission — represents a paradigm shift for a notoriously deadly cancer and begins what analysts see as a highly lucrative drug launch.
- The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A protein might be against the condition.
- Faced with a dwindling bank account after a series of research setbacks, Biohaven is letting go of its most advanced experimental drug in a deal one analyst viewed as a “surprising” transaction.
- A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.
- Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.
- Labcorp and Quest Diagnostics both plan to offer the test, which secured CE mark certification earlier this year.
Thông tin từ STAT News
- RFK Jr. downplays measles threat, FDA approves pancreatic drug, and more health news from Morning Rounds
- The report raises a high-profile issue for Heidi Overton as she faces confirmation as FDA commissioner.
- The European Society of Cardiology Congress that kicks off Friday in Munich will be a consequential meeting for Alnylam Pharmaceuticals.
- “The menopause symptoms women are discussing online should become the questions researchers ask next,” writes researcher Yulin Hswen.
- “Biotech industry leaders must forge a new geographic path before heavy-handed legislation forces the issue,” write executives at Optimapharm.
- Inside health systems' efforts to mitigate massive funding cuts.
Thông tin từ Nature Review Drug Discovery
- Nature Reviews Drug Discovery, Published online: 26 August 2026; doi:10.1038/d41573-026-00139-wSmall molecule boosts Parkinson disease treatment
- Nature Reviews Drug Discovery, Published online: 24 August 2026; doi:10.1038/s41573-026-01517-0Transcriptional CDKs coordinate gene expression throughout the transcription cycle and are increasingly recognized as therapeutic targets. This Review examines their roles in cancer-associated transcriptional dysregulation and highlights emerging strategies to modulate transcriptional CDKs for therapeutic benefit.
- Nature Reviews Drug Discovery, Published online: 24 August 2026; doi:10.1038/s41573-026-01509-0Drug discovery for psychiatric disorders is a slow and challenging process, driven in part by reliance on symptom-based diagnostic criteria that fail to capture the underlying disease biology. In their Perspective, Etkin and co-authors suggest a framework for a precision psychiatry approach, drawing on examples from […]
- Nature Reviews Drug Discovery, Published online: 12 August 2026; doi:10.1038/d41573-026-00136-zOncolytic virus nabs FDA approval
- Nature Reviews Drug Discovery, Published online: 10 August 2026; doi:10.1038/d41573-026-00135-0As Takeda’s oveporexton (Orzeyful) becomes a first-in-class treatment for narcolepsy type 1, industry eyes broader indications for orexin receptor agonists.
- Nature Reviews Drug Discovery, Published online: 07 August 2026; doi:10.1038/s41573-026-01496-2Applications of artificial intelligence (AI) in drug discovery have attracted high interest in recent years, but evidence for clinically relevant impact so far is limited. This Perspective discusses potential reasons, including an insufficient focus on clinical translation during model development and difficulties with applying AI algorithms […]